Discovery of Potent and Selective Reversible Ubiquitin-Like Modifier Activating Enzyme 5 Inhibitors Targeting the UFMylation Pathway
- 25 September 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (19) , 20827-20845
Abstract
Ubiquitin-like modifier activating enzyme 5 (UBA5), an E1 enzyme in the UFMylation pathway, is of interest as a therapeutic target in diseases such as cancer due to the critical role that UFMylation plays in cellular function. Strategic structure–activity relationship optimization of high-throughput screen hit 6, a Bruton’s tyrosine kinase covalent inhibitor, was conducted by using both conventional and microscale library synthesis. This approach identified 49 and 50 as potent and selective noncovalent UBA5 inhibitors with significantly improved surface plasmon resonance and nanodifferential scanning fluorimetry biophysical profiles. Cellular target engagement for 49 and 50 was confirmed by a cellular thermal shift assay and translated to inhibition of UFMylation of UBA5 and UFC1 in retinal pigment epithelial-1 cells as well as reduction of UFMylation of the downstream protein UFMylation substrate RPL26. Furthermore, 49 and 50 demonstrated specificity for UBA5 among the other E1–E2 transesterification pathways. In this communication, we report the discovery and synthesis of potent and selective UBA5 inhibitors, providing valuable tool compounds for studying the UFMylation pathway.Keywords
This publication has 37 references indexed in Scilit:
- Protein UFMylation regulates early events during ribosomal DNA-damage responseCell Reports, 2024
- The UFM1 system: Working principles, cellular functions, and pathophysiologyMolecular Cell, 2023
- Optimizing drug discovery: Surface plasmon resonance techniques and their multifaceted applicationsChemical Physics Impact, 2023
- Emerging role of protein modification by UFM1 in cancerBiochemical and Biophysical Research Communications, 2022
- Electrochemistry combined-surface plasmon resonance biosensors: A reviewTrAC Trends in Analytical Chemistry, 2022
- Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of CancerJournal of Medicinal Chemistry, 2021
- An N-Terminal Extension to UBA5 Adenylation Domain Boosts UFM1 Activation: Isoform-Specific Differences in Ubiquitin-like Protein ActivationJournal of Molecular Biology, 2019
- Applications of Palladium-Catalyzed C–N Cross-Coupling ReactionsChemical Reviews, 2016
- Trans-Binding Mechanism of Ubiquitin-like Protein Activation Revealed by a UBA5-UFM1 ComplexCell Reports, 2016
- A selective inhibitor of the UFM1-activating enzyme, UBA5Bioorganic & Medicinal Chemistry Letters, 2016